Investor News The news contents can be obtained from our website December 09, 2010

Transcription

1 Investor News 2010 Bayer AG Investor Relations Leverkusen Germany The news contents can be obtained from our website Date December 20, 2010 December 17, 2010 December 13, 2010 December 10, 2010 December 09, 2010 November 22, 2010 November 18, 2010 November 17, 2010 November 03, 2010 News Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Central Retinal Vein Occlusion and in Diabetic Macular Edema - In Phase 3 study in CRVO, 56 percent of VEGF Trap-Eye patients gained at least 15 letters of vision compared to 12 percent in control group - In Phase 2 study in DME, patients in all VEGF Trap-Eye dose groups, including VEGF Trap-Eye dosed every two months, maintained or increased vision gains through 52-weeks FDA approves Bayer's new oral contraceptive Safyral Oral contraceptive raises folate levels, reducing the risk of neural tube defects Bayer CropScience and Evogene Sign Collaboration Agreement to Improve Wheat Seed - Focus on yield, drought tolerance and fertilizer use efficiency - Use of both advanced breeding and genetic modification methods New oral contraceptive regimen submitted for marketing authorization in the EU - Will support women in managing their menstrual cycle individually - Minimizes the number of bleedings - Innovative device, supporting women to follow an individualized intake regimen Capital expenditures of EUR 1 billion: Bayer plans to significantly expand capacities in China - Group sales in Greater China planned to increase to around EUR 5 billion by New MaterialScience production plants to be constructed and existing ones expanded - Expansion of research and development activities - Headquarters of the Polycarbonates Business Unit to move to Shanghai Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration - In both studies, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed every two months, achieved primary endpoint compared to ranibizumab dosed every month - Regulatory applications for marketing approval planned in first-half of 2011 More innovation, less administration Bayer focuses resources on growth and innovation - Major investment necessary in development pipeline, marketing and emerging markets - Annual savings of EUR 800 million planned from Planned net reduction of about 2,000 jobs worldwide by the end of 2012 Planned investment of EUR 110 million: Bayer MaterialScience increases downstream presence in China Five new facilities to be completed by 2012 Bayer to strengthen Animal Health business in Asia Pacific and Latin America Bayer acquires Animal Health Company Bomac in New Zealand - Complementary portfolios with strong growth opportunities in combining both businesses - Creation of southern hemisphere hub to drive product innovation - 1 -

2 October 28, 2010 Interim report for the third quarter of 2010: Bayer lifts sales and earnings again - Sales grow by 16.1 percent to EUR 8,581 million - EBITDA before special items up 10.5 percent to EUR 1,656 million - Core earnings per share increase by 21.8 percent to EUR Provisions of EUR 436 million established for litigations - Net financial debt reduced by EUR 1.6 billion to EUR 9.1 billion - Group outlook for 2010 confirmed October 15, 2010 Multiple Sclerosis: 21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment Study provides the first and only survival data for any multiple sclerosis (MS) treatment October 11, 2010 EU regulators okay Qlaira for the treatment of heavy menstrual bleeding September 27, 2010 U.S. approval for a new oral contraceptive: Bayer receives approval for Beyaz in the U.S. - First and only contraceptive to raise folate levels, reducing the risk of neural tube defects - First and only FDA-approved birth control pill with four indications September 09, 2010 Solutions from sowing to the harvest: Bayer CropScience plans to further expand business with high-margin products and new crops - Friedrich Berschauer hands over reins to Sandra E. Peterson - New crop protection agents with peak sales potential of more than EUR 1 billion - BioScience Business Unit plans around 18 new products by 2016 September 06, 2010 September 01, 2010 August 31, 2010 August 30, 2010 August 04, 2010 August 04, 2010 LEVITRA 10mg Orodispersible Tablet for the Treatment of Erectile Dysfunction approved in Europe New formulation expected to be launched in November 2010 Further milestone to strengthen cereal product portfolio: New fungicidal active ingredient Bixafen registered in the United Kingdom for the first time Global peak sales potential of about EUR 300 million Treatment of Deep Vein Thrombosis: Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use - Bayer's dermatology subsidiary Intendis prepares to enter aesthetics segment - Joint development of first-in-class injectable drug for minimally invasive facial fat reduction Bayer's Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN- DVT Study - Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study - Rivaroxaban well tolerated in this long-term trial - Full data set to be presented at Hot Line Session at ESC 2010 FDA Accepts New Drug Application for Gadovist 1.0 Injection in Magnetic Resonance Imaging - 2 -

3 July 29, 2010 July 15, 2010 June 21, 2010 June 17, 2010 June 17, 2010 June 15, 2010 June 14, 2010 May 20, 2010 May 18, 2010 May 14, 2010 May 07, 2010 May 07, 2010 May 05, 2010 MaterialScience leaves the crisis behind Bayer increases sales and earnings in the second quarter - Sales grow by 14.6 percent to EUR 9,179 million - EBITDA before special items up 8.6 percent to EUR 1,917 million - Core earnings per share increase by 9.5 percent to EUR Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion - Group outlook confirmed for 2010 New rice fungicide isotianil granted regulatory approval in Japan Routine already successfully launched in Korea New erectile dysfunction treatment STAXYN approved in the U.S. Orodispersible formulation of Levitra (vardenafil HCI) soon available Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway Results from Phase III EINSTEIN-DVT Study with Bayer's Rivaroxaban to be Presented at Hot Line Session at ESC 2010 Bayer sues Teva and Barr for false advertising and patent infringement in connection with Teva's generic oral contraceptive Gianvi - Gianvi s label falsely claims that its formula and product, now in the US market, contains the same product stabilizer as YAZ (drospirenone & ethinyl estradiol) Bayer s oral contraceptive - Suit filed in the Northern District of Illinois (Chicago) Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival - Positive Secondary Endpoint of Progression Free Survival - Clinical Trial Program in Lung Cancer Ongoing New choices for cotton growers: Bayer CropScience and Dow AgroSciences sign global cotton technology cross-licensing agreements American Thoracic Society (ATS) Congress 2010, New Orleans, USA: Bayer Presents New Riociguat Phase II Data - First Phase II study in patients with pulmonary hypertension owing to interstitial lung disease meets primary objectives - First long-term extension data of Phase II study in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension show sustained improvement in exercise capacity Bayer MaterialScience raises prices for polyurethane raw materials US approval for the indication pregnancy prevention: Bayer receives approval for its new oral contraceptive in the U.S. - The first and only contraceptive to bring estradiol valerate together with dienogest in a new dosing regimen - Product will be marketed as Natazia in the U.S. Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization of Treatment for Vaginal Atrophy and Female Sexual Dysfunction - 3 -

4 April 30, 2010 CEO Werner Wenning at the Annual Stockholders' Meeting of Bayer AG: "We plan to grow again" operationally a strong year in a difficult environment - Bayer stock performance in 2009: plus 40 percent - Proposal to pay an unchanged dividend of EUR 1.40 per share for Strong gains in sales and earnings in the first quarter of Personnel changes on the Board of Management and the Supervisory Board April 29, 2010 Interim report for the first quarter of 2010: Bayer achieves strong gains in sales and earnings - Sales advance by 5.3 percent to EUR 8,316 million - EBITDA before special items climbs by 13.2 percent to EUR 1,918 million - Net income up 63.1 percent to EUR 693 million - Core earnings per share increase by 31.9 percent to EUR Group outlook raised for 2010 April 27, 2010 Sandra E. Peterson appointed new Chairman of the Board of Management of Bayer CropScience - Current Chairman Prof. Friedrich Berschauer to retire - Achim Noack appointed to the Board of Management of Bayer CropScience - Dr. Dirk Van Meirvenne to be Managing Director of Bayer Technology Services April 21, 2010 Leadership change effective August 15, 2010: Dr. Jörg Reinhardt appointed new CEO of Bayer HealthCare - Arthur Higgins to leave the company at the end of April - Dr. Marijn Dekkers to head the subgroup temporarily as of May 1 April 19, 2010 March 26, 2010 Bayer CropScience: verdict in Arkansas biotech rice trial incomprehensible Company acted responsibly and appropriately at all times CHMP's Pharmacovigilance Working Party completes review: Bayer will update Yasmin label in the EU Positive benefit/risk profile of Yasmin confirmed March 10, 2010 MR contrast agents for diagnosis of breast cancer Bayer starts Phase III study to evaluate efficacy and safety of Gadovist in magnetic resonance mammography March 01, 2010 Approval process begins in April 2010: Bayer MaterialScience planning new world-scale TDI plant at Dormagen site - EUR 150 million investment in the future - New production process was developed in Dormagen - Energy savings of up to 60 percent versus conventional plants February 26, 2010 February 26, 2010 February 24, 2010 Bayer modifies Board of Management compensation system - Reduction of short-term incentive and strengthening of long-term compensation component - Extended share retention period under long-term incentive program - Increased personal investment in Bayer stock - Adjustments effective January 1, Compensation system to be submitted to Annual Stockholders' Meeting for approval 2009: operationally one of the strongest years - optimism for the future Bayer successful in a difficult environment - Group sales EUR 31,168 million (minus 5.3 percent) - EBITDA before special items EUR 6,472 million (minus 6.6 percent) - Net income EUR 1,359 million (minus 20.9 percent) - Net cash flow significantly improved to EUR 5,375 million (plus 49 percent) - Net financial debt reduced by EUR 4.5 billion to EUR 9.7 billion - Core earnings per share expected to improve by about 10 percent in 2010 Bayer proposes dividend for 2009 of EUR 1.40 per share - 4 -

5 February 18, 2010 January 25, 2010 VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema - Statistically significant improvement in vision achieved over 24 weeks - Results to be presented at the Angiogenesis Clinical Trials meeting in Miami, Florida on February 20, 2010 Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis - Study will not be able to meet primary endpoint - Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development - 5 -